메뉴 건너뛰기
Archives of Dermatology
Volumn 136, Issue 1, 2000, Pages 71-73
Melanoma and the dermatologist in the third millennium
Author keywords

[No Author keywords available]
Indexed keywords

BCG VACCINE; INTERFERON; MELANOMA VACCINE;
EID: 0033982601     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.136.1.71     Document Type: Article
Times cited : (9)
References (8)
  • 1
    • 0032925323 scopus 로고    scopus 로고
    • Analysis of the melanoma epidemic, both apparent and real
    • Dennis LK. Analysis of the melanoma epidemic, both apparent and real. Arch Dermatol. 1999;135:275-280.
    • (1999) Arch Dermatol. , vol.135 , pp. 275-280
    • Dennis, L.K.1
  • 2
    • 0024814687 scopus 로고
    • Model predicting survival in stage I melanoma based on tumor progression
    • Clark WH Jr, Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
    • (1989) J Natl Cancer Inst. , vol.81 , pp. 1893-1904
    • Clark W.H., Jr.1    Elder, D.E.2    Guerry D. IV3
  • 3
    • 0026590057 scopus 로고
    • Technical details of intraoperative lymphatic mapping for early stage melanoma
    • Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
    • (1992) Arch Surg. , vol.127 , pp. 392-399
    • Morton, D.L.1    Wen, D.R.2    Wong, J.H.3
  • 4
    • 0032977814 scopus 로고    scopus 로고
    • Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
    • Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983.
    • (1999) J Clin Oncol. , vol.17 , pp. 976-983
    • Gershenwald, J.E.1    Thompson, W.2    Mansfield, P.F.3
  • 5
    • 0033009823 scopus 로고    scopus 로고
    • Outcome of patients with melanoma and histologically negative sentinel lymph nodes
    • Gadd MA, Cosimi AB, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134:381-387.
    • (1999) Arch Surg. , vol.134 , pp. 381-387
    • Gadd, M.A.1    Cosimi, A.B.2    Yu, J.3
  • 6
    • 0030030347 scopus 로고    scopus 로고
    • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
    • Kirkwood JM, Strawderman MK, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14: 7-17.
    • (1996) J Clin Oncol. , vol.14 , pp. 7-17
    • Kirkwood, J.M.1    Strawderman, M.K.2    Ernstoff, M.S.3    Smith, T.J.4    Borden, E.C.5    Blum, R.H.6
  • 7
    • 0006742938 scopus 로고    scopus 로고
    • Results of the French multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (>1.5 mm)
    • Grob JJ, Dreno B, Delaunay M, et al. Results of the French multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (>1.5 mm) [abstract]. Proc Am Soc Clin Oncol. 1996;15:437.
    • (1996) Proc Am Soc Clin Oncol. , vol.15 , pp. 437
    • Grob, J.J.1    Dreno, B.2    Delaunay, M.3
  • 8
    • 7144264391 scopus 로고    scopus 로고
    • Adjuvant Interferon alfa-2a treatment in resected primary stage II cutaneous melanoma
    • Pehamberger H, Soyer HP, Steiner A. et al. Adjuvant Interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol. 1998;16: 1425-1429.
    • (1998) J Clin Oncol. , vol.16 , pp. 1425-1429
    • Pehamberger, H.1    Soyer, H.P.2    Steiner, A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.